作者
Mohd Aslam Saifi, Sapana Bansod, Chandraiah Godugu
发表日期
2022/11/1
来源
Drug Discovery Today
卷号
27
期号
11
页码范围
103345
出版商
Elsevier Current Trends
简介
Highlights
- The development of fibrosis in COVID-19 survivors is a major concern.
- Although, the fibrosis is resolved over time, there is a concern of residual effects of viral infection in the COVID-19 patients.
- The clinical cases of different organ fibrosis in COVID-19 survivors warrants our attention.
Coronavirus 2019 (COVID-19), caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has had significant impacts worldwide since its emergence in December, 2019. Despite a high recovery rate, there is a growing concern over its residual, long-term effects. However, because of a lack of long-term data, we are still far from establishing a consensus on post-COVID-19 complications. The deposition of excessive extracellular matrix (ECM), known as fibrosis, has been observed in numerous survivors of COVID-19. Given the exceptionally high number of individuals affected, there is an urgent need to address …
学术搜索中的文章
MA Saifi, S Bansod, C Godugu - Drug Discovery Today, 2022